Brady’s growth leads to strategy upgrade

Brady plc, supplier of trading and risk management software for metals and commodities, said that in light of its rapid growth, it is changing its development, release and implementation strategy for 2009.

CEO Gavin Lavelle said: "The last 18 months have seen some of the most significant growth in the company's history and this has required everyone in the business to re-evaluate the core structures and to look at how best to deliver a highly scalable business model in terms of development, support and client interaction.

"The new software development and management processes enable Brady to enhance customer satisfaction and allow greater scalability for the planned future growth."

The company said the main benefits for customers will be easier implementations and upgrades and an overall reduction in the cost of ownership. This will be achieved through a scalable approach to development with additional prioritisation criteria focused on the changing requirements of the metals markets.

In the past 18 months Brady has secured nine new clients, accelerated product development and added headcount and offices. The extra customers have led to a greater demand for special projects, in turn necessitating a global perspective in the prioritisation of product development, release management and support.

All future releases of Brady Trinity will now be restricted to an annual version release with subsequent service packs to be released on alternate months, with a maximum of six a year.

Brady said it clients include many of the world's largest miners, refiners and producers as well as tier one banks and a large number London Metal Exchange category 1 and 2 clearing members.

At 52.50p, Brady's shares are trading at a 52-week high. The company is valued at around £14.5m.

 



Previous articles
Briefs: Pfizer to open stem cell R&D ops in Cambridge; CAMBfix secures funding
CSR says Q3 sales likely to be up to 10% lower than expected
Briefs: CAT to double in size; Alizyme’s 1H08 loss narrows but sees delay in progress of key treatment
Briefs: Agilent, Spirent join CSR in EGPS Forum; Stem Cell Sciences launches iStem
Domino acquires its Portuguese distributor for €7m
Minster Pharma files patent for schizophrenia drug; confident of success
Xaar shares slide 22% as some Chinese customers investigated over import duties
CSR reports strong Q307 growth; launches cheap internet radio chip
Autonomy to beat 1Q09 revenue forecasts; signs licence deal with T-Mobile
Acambis steps up R&D spending; aborts pursuit of 'major acquisition'
Subscribe

 

Managed Hosting by NTT Managed Hosting
SEO London by IdeaTaxi.com
Corporate profiles

 • NovaThera


Dr Rob Daniels
Chief Commercial Officer


NovaThera Ltd specialises in pioneering applications of biomaterials and stem cell biology for regenerative medicine and tissue engineering to provide innovative therapeutic solutions. It was spun-out of Imperial College London in 2003. NovaThera has a relationship with Imperial College to continue

[NovaThera's profile]


Top20 Index




Currently: 129.81

Best Deal Mortgages
If debt is becoming a problem, click here for the best deal mortgages.

marcusevans
See why many companies believe Marcus Evans gives the most fulfilling, interesting and enjoyable training courses ever!

Marcus Evans Scam
Combat corruption in your company by attending a Marcus Evans scam conference.

IFL
IFL are leaders in the Chrome industry. To find out more visit www.ifml.com